Skip to main content
logo
Obsidian Therapeutics, Inc. (OBX)
NASDAQ: OBX · Real-Time Price · USD
16.82
-0.27 (-1.58%)
Sep 4, 2026, 4:00 PM EDT - Market closed

Obsidian Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Income
-94.22-100.61-83.11
Depreciation & Amortization
1.371.481.53
Loss (Gain) From Sale of Investments
-1.4-2.61-2.21
Stock-Based Compensation
7.078.937.06
Other Operating Activities
-0.19-0.14-0.03
Change in Accounts Payable
-0.11-1.810.7
Change in Other Net Operating Assets
-4.384.361.05
Operating Cash Flow
-91.81-90.39-75
Operating Cash Flow Growth
---

Investing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Capital Expenditures
-0.02-0.07-0.78
Investment in Securities
74.2881.09-53.1
Investing Cash Flow
74.2981.02-53.87

Financing Activities

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Issuance of Common Stock
0.850.022.55
Other Financing Activities
---0.53
Financing Cash Flow
0.850.02162.52

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Net Cash Flow
-16.68-9.3633.64

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Free Cash Flow
-91.83-90.47-75.78
Free Cash Flow Growth
---
Free Cash Flow Per Share
-4.14-1848.92-
Levered Free Cash Flow
--52.94-
Unlevered Free Cash Flow
--52.94-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024
Period Ending
Jun '26 Dec '25 Dec '24
Change in Working Capital
-4.52.561.75
SEC Filings: 10-K · 10-Q